Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 18.17
DXCM's Cash to Debt is ranked higher than
77% of the 295 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.82 vs. DXCM: 18.17 )
DXCM' s 10-Year Cash to Debt Range
Min: 0.6   Max: No Debt
Current: 18.17

Equity to Asset 0.76
DXCM's Equity to Asset is ranked higher than
85% of the 287 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.62 vs. DXCM: 0.76 )
DXCM' s 10-Year Equity to Asset Range
Min: -0.44   Max: 0.88
Current: 0.76

-0.44
0.88
F-Score: 7
Z-Score: 69.60
M-Score: -3.20
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) -8.29
DXCM's Operating margin (%) is ranked higher than
66% of the 289 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.79 vs. DXCM: -8.29 )
DXCM' s 10-Year Operating margin (%) Range
Min: -2272.81   Max: -8.29
Current: -8.29

-2272.81
-8.29
Net-margin (%) -8.64
DXCM's Net-margin (%) is ranked higher than
67% of the 289 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.80 vs. DXCM: -8.64 )
DXCM' s 10-Year Net-margin (%) Range
Min: -2147.42   Max: -8.64
Current: -8.64

-2147.42
-8.64
ROE (%) -21.18
DXCM's ROE (%) is ranked higher than
63% of the 273 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.68 vs. DXCM: -21.18 )
DXCM' s 10-Year ROE (%) Range
Min: -60327.45   Max: -19.97
Current: -21.18

-60327.45
-19.97
ROA (%) -15.32
DXCM's ROA (%) is ranked higher than
63% of the 299 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.00 vs. DXCM: -15.32 )
DXCM' s 10-Year ROA (%) Range
Min: -178.43   Max: -14.59
Current: -15.32

-178.43
-14.59
ROC (Joel Greenblatt) (%) -56.22
DXCM's ROC (Joel Greenblatt) (%) is ranked higher than
65% of the 298 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.49 vs. DXCM: -56.22 )
DXCM' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -3333.88   Max: -50.89
Current: -56.22

-3333.88
-50.89
Revenue Growth (3Y)(%) 43.80
DXCM's Revenue Growth (3Y)(%) is ranked higher than
98% of the 212 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.20 vs. DXCM: 43.80 )
DXCM' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0   Max: 103.1
Current: 43.8

0
103.1
EBITDA Growth (3Y)(%) -35.00
DXCM's EBITDA Growth (3Y)(%) is ranked higher than
57% of the 194 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.90 vs. DXCM: -35.00 )
DXCM' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 0   Max: 0.6
Current: -35

0
0.6
EPS Growth (3Y)(%) -23.90
DXCM's EPS Growth (3Y)(%) is ranked higher than
61% of the 185 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.20 vs. DXCM: -23.90 )
DXCM' s 10-Year EPS Growth (3Y)(%) Range
Min: -40.1   Max: 37.1
Current: -23.9

-40.1
37.1
» DXCM's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

DXCM Guru Trades in Q1 2014

Steven Cohen 13,332 sh (New)
RS Investment Management 496,081 sh (+3.92%)
Ron Baron 1,354,112 sh (-0.24%)
Mario Gabelli 71,000 sh (-4.05%)
Paul Tudor Jones 7,198 sh (-10.68%)
Jim Simons 380,843 sh (-31.69%)
» More
Q2 2014

DXCM Guru Trades in Q2 2014

Joel Greenblatt 8,033 sh (New)
RS Investment Management 538,660 sh (+8.58%)
Paul Tudor Jones Sold Out
Jim Simons Sold Out
Ron Baron 1,348,572 sh (-0.41%)
Mario Gabelli 70,500 sh (-0.70%)
» More
Q3 2014

DXCM Guru Trades in Q3 2014

Joel Greenblatt Sold Out
Ron Baron 1,345,322 sh (-0.24%)
Mario Gabelli 66,000 sh (-6.38%)
RS Investment Management 433,460 sh (-19.53%)
» More
Q4 2014

DXCM Guru Trades in Q4 2014

Jim Simons 269,343 sh (New)
Joel Greenblatt 9,915 sh (New)
RS Investment Management 535,254 sh (+23.48%)
Ron Baron 1,340,731 sh (-0.34%)
Mario Gabelli 51,600 sh (-21.82%)
» More
» Details

Insider Trades

Latest Guru Trades with DXCM

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Top Ranked Articles about DexCom Inc

Top Insider Sells Highlight: Dexcom Inc.
CEO, 10% Owner of Dexcom Inc (DXCM) Terrance H Gregg sold 23,893 shares on 08/21/2014 at an average price of $44.36. The total transaction amount was $1,059,893. Read more...

Ratios

vs
industry
vs
history
Forward P/E 144.93
DXCM's Forward P/E is ranked higher than
68% of the 333 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. DXCM: 144.93 )
N/A
P/B 38.10
DXCM's P/B is ranked lower than
64% of the 333 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.70 vs. DXCM: 38.10 )
DXCM' s 10-Year P/B Range
Min: 3.88   Max: 209.25
Current: 38.1

3.88
209.25
P/S 20.14
DXCM's P/S is ranked lower than
65% of the 333 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.43 vs. DXCM: 20.14 )
DXCM' s 10-Year P/S Range
Min: 6.36   Max: 1058.5
Current: 20.14

6.36
1058.5
PFCF 771.40
DXCM's PFCF is ranked higher than
69% of the 333 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. DXCM: 771.40 )
DXCM' s 10-Year PFCF Range
Min: 578.57   Max: 783.9
Current: 771.4

578.57
783.9
POCF 220.71
DXCM's POCF is ranked higher than
74% of the 333 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. DXCM: 220.71 )
DXCM' s 10-Year POCF Range
Min: 155.77   Max: 1503.33
Current: 220.71

155.77
1503.33
Current Ratio 3.59
DXCM's Current Ratio is ranked higher than
77% of the 296 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.52 vs. DXCM: 3.59 )
DXCM' s 10-Year Current Ratio Range
Min: 1.96   Max: 20.46
Current: 3.59

1.96
20.46
Quick Ratio 3.20
DXCM's Quick Ratio is ranked higher than
79% of the 295 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.16 vs. DXCM: 3.20 )
DXCM' s 10-Year Quick Ratio Range
Min: 1.82   Max: 20.46
Current: 3.2

1.82
20.46
Days Inventory 52.66
DXCM's Days Inventory is ranked higher than
83% of the 333 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 138.68 vs. DXCM: 52.66 )
DXCM' s 10-Year Days Inventory Range
Min: 23.53   Max: 73.69
Current: 52.66

23.53
73.69
Days Sales Outstanding 59.71
DXCM's Days Sales Outstanding is ranked higher than
81% of the 333 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 77.03 vs. DXCM: 59.71 )
DXCM' s 10-Year Days Sales Outstanding Range
Min: 16.96   Max: 71.25
Current: 59.71

16.96
71.25

Valuation & Return

vs
industry
vs
history
Price/Net Cash 136.10
DXCM's Price/Net Cash is ranked higher than
72% of the 333 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. DXCM: 136.10 )
DXCM' s 10-Year Price/Net Cash Range
Min: 5.94   Max: 160.95
Current: 136.1

5.94
160.95
Price/Net Current Asset Value 68.10
DXCM's Price/Net Current Asset Value is ranked higher than
65% of the 333 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. DXCM: 68.10 )
DXCM' s 10-Year Price/Net Current Asset Value Range
Min: 5.57   Max: 47.21
Current: 68.1

5.57
47.21
Price/Tangible Book 39.70
DXCM's Price/Tangible Book is ranked lower than
53% of the 333 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 10.60 vs. DXCM: 39.70 )
DXCM' s 10-Year Price/Tangible Book Range
Min: 4.7   Max: 154.75
Current: 39.7

4.7
154.75
Price/Median PS Value 1.40
DXCM's Price/Median PS Value is ranked higher than
64% of the 333 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.40 vs. DXCM: 1.40 )
DXCM' s 10-Year Price/Median PS Value Range
Min: 0.54   Max: 8.36
Current: 1.4

0.54
8.36
Earnings Yield (Greenblatt) -0.40
DXCM's Earnings Yield (Greenblatt) is ranked higher than
66% of the 296 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.20 vs. DXCM: -0.40 )
DXCM' s 10-Year Earnings Yield (Greenblatt) Range
Min: -0.6   Max: 0
Current: -0.4

-0.6
0

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:WST, BAX, COV, TMO, COO » details
Traded in other countries:DC4.Germany,
DexCom Inc designs, develops and commercializes continuous glucose monitoring systems for ambulatory use by people with diabetes and for use by healthcare providers in the hospital for the treatment of both diabetic and non-diabetic patients. The majority of its product revenue comes from sales of its SEVEN PLUS ambulatory continuous glucose monitoring system. The Company's SEVEN PLUS and G4 PLATINUM systems are more invasive than current self-monitored glucose testing systems, including single-point finger stick devices, and patients may be unwilling to insert a sensor in their body, especially if their current diabetes management involves no more than two finger sticks per day. Moreover, patients may not perceive the benefits of continuous glucose monitoring and may be unwilling to change their current treatment regimens. As compared to the SEVEN PLUS, the G4 PLATINUM offers additional user interface and algorithm enhancements that are intended to make its glucose monitoring function more accurate especially in the hypoglycemic range. To address the in-hospital patient population, it entered into an exclusive agreement with Edwards to develop jointly and market a specific product platform for the in-hospital glucose monitoring market, with an initial focus on the development of an intravenous sensor specifically for the critical care market. Its products also shows how fast the body's glucose levels are changing. It is designed to help avoid highs and lows and to help keep the glucose between the lines of the target zones. Its competitors include Roche Disetronic, Roche Diagnostics, LifeScan, Inc, Johnson & Johnson, the MediSense and Abbott Laboratories, and Bayer Corporatio. Its products are medical devices subject to extensive and ongoing regulation by the FDA and regulatory bodies in other countries.
» More Articles for DXCM

Headlines

Articles On GuruFocus.com
Dexcom’s Smart Glucose Monitoring System Receives FDA Approval Jan 27 2015 
Top Insider Sells Highlight: Dexcom Inc. Aug 22 2014 
DexCom Reports $1 Million Insider Buy Mar 12 2013 
DexCom Inc. Reports Operating Results (10-Q) Aug 03 2010 
DexCom Inc. Reports Operating Results (10-Q) May 05 2010 
DexCom Inc. Reports Operating Results (10-Q) Nov 04 2009 
DexCom Inc. Reports Operating Results (10-Q) Aug 03 2009 
DexCom Inc. Reports Second Quarter 2009 Financial Results Aug 03 2009 
DexCom Inc. (DXCM) CEO Terrance H Gregg buys 20,000 Shares May 14 2009 
DexCom Inc. Reports Operating Results (10-Q) May 06 2009 

More From Our Partners
DexCom Launches CGM App on Apple Watch; Shares Rise - Analyst Blog Apr 13 2015 - ZACKS

More From Other Websites
The Zacks Analyst Blog Highlights: Apple, DexCom, athenahealth and Cerner - Press Releases Apr 24 2015
Apple Watch Puts These 3 Health Stocks in Focus - Analyst Blog Apr 23 2015
DexCom Announces Upcoming Conference Presentations Apr 22 2015
DexCom Announces Upcoming Conference Presentations Apr 22 2015
United Therapeutics Corporation (UTHR), Amgen, Inc. (AMGN): Neil Shah’s Top Healthcare Picks... Apr 16 2015
[$$] Johnson & Johnson Trends Favor Four Stocks Apr 15 2015
DexCom Launches CGM App on Apple Watch; Shares Rise - Analyst Blog Apr 13 2015
DexCom Hits 52-Week High on Q4 Results, Estimate Revision - Analyst Blog Apr 10 2015
DexCom Schedules First Quarter 2015 Earnings Release and Conference Call for April 29, 2015 at 4:30... Apr 10 2015
Dexcom® Introduces Apps That Enable the First Ever Continuous Glucose Monitoring (CGM) on the Apple... Apr 10 2015
DexCom Schedules First Quarter 2015 Earnings Release and Conference Call for April 29, 2015 at 4:30... Apr 10 2015
Dexcom® Introduces Apps That Enable the First Ever Continuous Glucose Monitoring (CGM) on the Apple... Apr 10 2015
DEXCOM INC Financials Mar 05 2015
10-K for DexCom, Inc. Feb 27 2015
DexCom, Inc. Reports Fourth Quarter and Full Year 2014 Financial Results Feb 26 2015
DexCom Reports Earnings in Q4, Top Line Surges Y/Y - Analyst Blog Feb 26 2015
DexCom tops 4Q profit forecasts Feb 25 2015
DexCom tops 4Q profit forecasts Feb 25 2015
DexCom Inc Earnings Call scheduled for 4:30 pm ET today Feb 25 2015
DEXCOM INC Files SEC form 8-K, Results of Operations and Financial Condition, Change in Directors or... Feb 25 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK